Communiqués AbbVie Inc. London S.E.

Actions

0QCV

US00287Y1091

Marché Fermé - London S.E. Autres places de cotation 17:30:00 05/07/2024			Varia. 5j.	Varia. 1 janv.
164,8 ^USD	+0,07%		-3,16%	+6,60%

05/07	AbbVie annonce une baisse de son bénéfice ajusté au deuxième trimestre en raison des dépenses de recherche et développement, et révise ses perspectives pour 2024	MT
04/07	En Direct des Marchés : Sanofi, TotalEnergies, Airbus, Eramet, Dassaut Systèmes, KKR, Ford...

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

AbbVie : Results of Operations and Financial Condition Form 8 K	03/07	PU
AbbVie to Host Second-Quarter 2024 Earnings Conference Call	02/07	PR
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer	01/07	PR
AbbVie - Introducing Alle Payment Plans, Powered by Cherry	28/06	AQ
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	28/06	PR
AbbVie Acquires Celsius Therapeutics	27/06	PR
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06	AQ
Introducing Allē Payment Plans, Powered by Cherry	27/06	PR
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06	PR
AbbVie Provides U.S. Regulatory Update on ABBV-951	26/06	AQ
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	25/06	PR
AbbVie Declares Quarterly Dividend	24/06	AQ
AbbVie Declares Quarterly Dividend	21/06	PR
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors	20/06	PR
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease	19/06	PR
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer	14/06	PR
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease	13/06	PR
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients	11/06	PR
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers	07/06	AQ
AbbVie - SkinMedica Celebrates 25 Years of Empowering Radiant Skin	07/06	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués AbbVie Inc. London S.E.

Actions

0QCV

US00287Y1091

Communiqués

Filtres